Heparin-binding epidermal growth factor (EGF)-like growth factor (HB-EGF), which binds to the EGF receptor, plays an important role in the occurrence and development of inflammation in various diseases. HB-EGF mediates the progression of ovarian cancer and is associated with disease prognosis. Thus, a specific humanized antibody to HB-EGF with high affinity is important.
Methods:
In this study, a humanized domain antibody (VH) against HB-EGF was discovered through phage display technology. The domain antibody was expressed in HB2151 cells and purified from the supernatant using protein L, and were used to test the its effect in invasion and migration of ovarian cancer SKOV3.
Results:
A domain antibody against HB-EGF was discovered, with a dissociation constant of ∼30 nM. Functional assays indicated that the domain antibody inhibited the functions of HB-EGF in promoting invasion and migration of SKOV3 cells.
Conclusions:
The selected domain antibody is a potential tool for developing novel drugs or therapies to combat ovarian cancer.
Get full access to this article
View all access options for this article.
References
1.
SiromolotAA, KryninaOI, KolyboDV, et al.Antiproliferative and apoptotic effects of anti-human HB-EGF neutralizing polyclonal antibodies in vitro. Exp Oncol, 2020; 42:25.
2.
ShahBH, FarshoriMP, JambusariaA, et al.Roles of Src and epidermal growth factor receptor transactivation in transient and sustained ERK1/2 responses to gonadotropin-releasing hormone receptor activation. J Biol Chem, 2003; 278:19118.
3.
SuY, LuoH, YangJ. Heparin-binding EGF-like growth factor attenuates lung inflammation and injury in a murine model of pulmonary emphysema. Growth Factors, 2018; 36:246.
LiZ, YanH, YuanJ, et al.Pharmacological inhibition of heparin-binding EGF-like growth factor promotes peritoneal angiogenesis in a peritoneal dialysis rat model. Clin Exp Nephrol, 2018; 22:257.
6.
KivelaR, HemanthakumarKA, VaparantaK, et al.Endothelial cells regulate physiological cardiomyocyte growth via VEGFR2-mediated paracrine signaling. Circulation, 2019; 139:2570.
7.
RadulescuA, YuX, OrvetsND, et al.Deletion of the heparin-binding epidermal growth factor-like growth factor gene increases susceptibility to necrotizing enterocolitis. J Pediatr Surg, 2010; 45:729.
8.
ZhouB, FanY, RaoJ, et al.Matrix metalloproteinases-9 deficiency impairs liver regeneration through epidermal growth factor receptor signaling in partial hepatectomy mice. J Surg Res, 2015; 197:201.
9.
SugiuraS, KitagawaK, TanakaS, et al.Adenovirus-mediated gene transfer of heparin-binding epidermal growth factor-like growth factor enhances neurogenesis and angiogenesis after focal cerebral ischemia in rats. Stroke, 2005; 36:859.
10.
EapenMS, SharmaP, ThompsonIE, et al.Heparin-binding epidermal growth factor (HB-EGF) drives EMT in patients with COPD: Implications for disease pathogenesis and novel therapies. Lab Invest, 2019; 99:150.
11.
LiuJ, RichCB, Buczek-ThomasJA, et al.Heparin-binding EGF-like growth factor regulates elastin and FGF-2 expression in pulmonary fibroblasts. Am J Physiol Lung Cell Mol Physiol, 2003; 285:L1106.
12.
IzuchiD, FukagawaS, YotsumotoF, et al.Association of serum HB-EGF value and response to chemotherapy in patients with recurrent ovarian cancer. Anticancer Res, 2018; 38:4347.
13.
GrunewaldT, LedermannJA. Targeted therapies for ovarian cancer. Best Pract Res Clin Obstet Gynaecol, 2017; 41:139.
14.
LianC, RuanL, ShangD, et al.Heparin-binding epidermal growth factor-like growth factor as a potent target for breast cancer therapy. Cancer Biother Radiopharm, 2016; 31:85.
15.
KasaiN, KobayashiK, ShioyaS, et al.Soluble heparin-binding EGF-like growth factor (HB-EGF) detected by newly developed immuno-PCR method is a clear-cut serological biomarker for ovarian cancer. Am J Transl Res, 2012; 4:415.
16.
MiyataK, YotsumotoF, FukagawaS, et al.Serum heparin-binding epidermal growth factor-like growth factor (HB-EGF) as a biomarker for primary ovarian cancer. Anticancer Res, 2017; 37:3955.
17.
TsujiokaH, YotsumotoF, HikitaS, et al.Targeting the heparin-binding epidermal growth factor-like growth factor in ovarian cancer therapy. Curr Opin Obstet Gynecol, 2011; 23:24.
18.
MiyamotoS, IwamotoR, FuruyaA, et al.A novel anti-human HB-EGF monoclonal antibody with multiple antitumor mechanisms against ovarian cancer cells. Clin Cancer Res, 2011; 17:6733.
19.
KasaiN, YoshikawaY, EnokizonoJ. Effect of antigen-dependent clearance on pharmacokinetics of anti-heparin-binding EGF-like growth factor (HB-EGF) monoclonal antibody. MAbs, 2014; 6:1220.
20.
Davis-FleischerKM, BesnerGE. Structure and function of heparin-binding EGF-like growth factor (HB-EGF). Front Biosci, 1998; 3:d288.
21.
NamSO, YotsumotoF, MiyataK, et al.Pre-clinical study of BK-UM, a novel inhibitor of HB-EGF, for ovarian cancer therapy. Anticancer Res, 2014; 34:4615.
22.
FukagawaS, YotsumotoF, OdawaraT, et al.Antitumour effects of intravenous administration of BK-UM, a novel inhibitor of HB-EGF, in ovarian cancer therapy. Anticancer Res, 2017; 37:3891.
23.
MiyamotoS, YotsumotoF, UedaT, et al.BK-UM in patients with recurrent ovarian cancer or peritoneal cancer: A first-in-human phase-I study. BMC Cancer, 2017; 17:89.
24.
MiyamotoS, YagiH, TanakaY. [HB-EGF is a promising target molecule for ovarian cancer]. Fukuoka Igaku Zasshi, 2004; 95:286.
25.
TangX, LuM, LiC, et al.[Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer]. Zhonghua Fu Chan Ke Za Zhi, 2014; 49:517.
NelsonAL. Antibody fragments: Hope and hype. MAbs, 2010; 2:77.
28.
BatesA, PowerCA. David vs. Goliath: The structure, function, and clinical prospects of antibody fragments. Antibodies (Basel), 2019; 8:28.
29.
FriguetB, ChaffotteAF, Djavadi-OhanianceL, et al.Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J Immunol Methods, 1985; 77:305.
30.
DaviesJ, RiechmannL. Antibody VH domains as small recognition units. Biotechnology (N Y), 1995; 13:475.
31.
HarmsenMM, De HaardHJ. Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol, 2007; 77:13.
32.
FreiseAC, WuAM. In vivo imaging with antibodies and engineered fragments. Mol Immunol, 2015; 67:142.
33.
KangX, CaoJ, ZhangB, et al.[Single-domain antibody—advances in research and application]. Sheng Wu Gong Cheng Xue Bao, 2018; 34:1974.
34.
ShenY, RuanL, LianC, et al.Discovery of HB-EGF binding peptides and their functional characterization in ovarian cancer cell lines. Cell Death Discov, 2019; 5:82.
35.
LeeCM, IornoN, SierroF, et al.Selection of human antibody fragments by phage display. Nat Protoc, 2007; 2:3001.
36.
FriguetB, ChaffotteAF, Djavadi-OhanianceL, et al.Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J Immunol Methods, 1985; 77:305.
37.
JanaCK, AliE. High resolution affinity chromatography of an anti-steroid antiserum by gradient elution with propionic acid. J Immunol Methods, 1999; 225:95.
38.
LeibigerH, HansenA, SchoenherrG, et al.Glycosylation analysis of a polyreactive human monoclonal IgG antibody derived from a human-mouse heterohybridoma. Mol Immunol, 1995; 32:595.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
